ImmunityBio(IBRX) - 2025 Q4 - Annual Results

Financial Results Announcement - ImmunityBio, Inc. announced preliminary, unaudited financial results for the fiscal quarter and full year ending December 31, 2025[4] - The reported financial results are based on preliminary estimates and may differ materially from actual results to be disclosed in the Annual Report on Form 10-K[4] - The financial results are subject to the Company's financial closing procedures and final adjustments[4] - The Company has not yet finalized its operating results and financial position for the fiscal year ended December 31, 2025[4] Press Release Information - The press release regarding these results was issued on January 15, 2026[4] - The information provided in the press release is not deemed "filed" under the Securities Exchange Act of 1934[5] - The press release is included as Exhibit 99.1 in the Current Report on Form 8-K[6] Company Information - The Company is listed on The Nasdaq Global Select Market under the symbol IBRX[2] - The Company is incorporated in Delaware and has its principal executive offices in San Diego, California[1] - David C. Sachs serves as the Chief Financial Officer of ImmunityBio, Inc.[9]